In Being Patient’s LiveTalk series, Dr. David Weidman, associate medical director for research at the Banner Alzheimer’s Institute, shares insights on Eli Lilly’s investigational Alzheimer’s…
This week, on the heels of Aduhelm’s FDA approval, the agency granted breakthrough status to two more prospective new Alzheimer’s treatments, Eli Lilly &…
We talked with Banner Alzheimer’s Institute Director Pierre Tariot about the most recent results from Eli Lilly’s Alzheimer’s trial for donanemab — what he…
This weekend, new batch of data from the TRAILBLAZER-ALZ trial for Eli Lilly’s Alzheimer’s drug donanemab was released, upholding the treatment’s ability to affect…
While Biogen’s experimental Alzheimer’s treatment aducanumab faced yet another snag recently in its convoluted path toward FDA approval, other drugs companies are catching up:…
Beta-amyloid plaques are a hallmark of Alzheimer’s, but researchers have long been puzzled about why these plaques can also be found in the brains…
New clinical trials on memory loss interventions is currently enrolling participants with key Alzhemier’s biomarkers as young as 55 and 60 years old. Tau…